Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences income Statement — Total revenues ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Operations (DB)
Latest, FY2025
29,443
Period ended Dec 31, 2025
Change on a year earlier
+2.4%
28,754 in FY2024
History
19 years
Since FY2007
Sources
15
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Income Statement — Total revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 29,443 | +2.4% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 28,754 | +6.0% | Form 10-K (filed 2025-02-28) ↗ |
| FY2023 | Dec 31, 2023 | 27,116 | -0.6% | Form 10-K (filed 2024-02-23) ↗ |
| FY2022 | Dec 31, 2022 | 27,281 | -0.1% | Form 10-K (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 27,305 | +10.6% | Form 10-K (filed 2022-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 24,689 | +10.0% | Form 10-K (filed 2021-02-25) ↗ |
| FY2019 | Dec 31, 2019 | 22,449 | +1.5% | Form 10-K (filed 2020-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 22,127 | -15.2% | Form 10-K (filed 2019-02-26) ↗ |
| FY2017 | Dec 31, 2017 | 26,107 | -14.1% | Form 10-K (filed 2018-02-27) ↗ |
| FY2016 | Dec 31, 2016 | 30,390 | -6.9% | Form 10-K (filed 2017-02-27) ↗ |
| FY2015 | Dec 31, 2015 | 32,639 | +31.1% | Form 10-K (filed 2016-02-24) ↗ |
| FY2014 | Dec 31, 2014 | 24,890 | +122.2% | Form 10-K (filed 2015-02-25) ↗ |
| FY2013 | Dec 31, 2013 | 11,202 | +15.5% | Form 10-K (filed 2015-02-25) ↗ |
| FY2012 | Dec 31, 2012 | 9,702 | +15.7% | Form 10-K (filed 2015-02-25) ↗ |
| FY2011 | Dec 31, 2011 | 8,385 | +5.5% | Form 10-K (filed 2012-02-23) ↗ |
| FY2010 | Dec 31, 2010 | 7,949 | +13.4% | Form 10-K (filed 2011-02-28) ↗ |
| FY2009 | Dec 31, 2009 | 7,011 | +31.4% | Form 10-K (filed 2010-03-01) ↗ |
| FY2008 | Dec 31, 2008 | 5,336 | +26.1% | Form 10-K (filed 2010-03-01) ↗ |
| FY2007 | Dec 31, 2007 | 4,230 | – | Form 10-K (filed 2010-03-01) ↗ |
Breakdown
What makes up income statement — total revenues ($m)
- Cost of goods sold ($M)6,234 · FY2025
- Research and development expenses ($M)5,799 · FY2025
- Selling, general and administrative expenses ($M)5,774 · FY2025
- Operating income (loss) ($M)10,022 · FY2025
- Interest expense ($M)1,024 · FY2025
- Income (loss) before income taxes ($M)9,796 · FY2025
- Income tax expense (benefit) ($M)1,286 · FY2025
- Net income (loss) attributable to Gilead ($M)8,510 · FY2025
- Diluted earnings (loss) per share ($/sh)6.78 · FY2025
- Diluted weighted-average shares (M shares)1,255 · FY2025
Cite this data
StockData. (2026). Gilead Sciences Income Statement — Total revenues ($M) ($M), annual FY2007–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/fs_income_stmt
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.